Cell technologies as a platform for personalized therapy: global challenges in oncology

Author:

Rykov M. Yu.1ORCID,Mentkevich G. L.2,Dolgopolov I. S.2ORCID

Affiliation:

1. Tver State Medical University; N.A. Semashko National Research Institute of Public Health

2. Tver State Medical University

Abstract

The incidence of various types of cancer is steadily increasing. It is necessary to correctly analyze and interpret statistical data, given that the quality of medical care at all its stages is characterized not by the level of morbidity, but by the mortality rate. The leading centers of the Russian Federation can apply almost all the therapy methods to treat patients. At the same time, one of the limiting factors for increasing the survival rate is the detection of diseases mainly at the late stages, which dictates the need to increase oncological alertness and the widespread introduction of early screening diagnostics into healthcare practice. The development of many new targeted drugs has led to the fact that only a few have been shown to be effective in the treatment of only certain types of tumors. The development of bone marrow transplantation contributed to the development of other directions in medicine, which proved that the hematopoietic stem cell is a platform for personalized therapy for many diseases. The article describes the problems of cell therapy implementation in the treatment of cancer patients.

Publisher

The National Academy of Pediatric Science and Innovation

Subject

Pediatrics, Perinatology and Child Health

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3